Federal funding for Inovio phase III is canceled and the stock loses one quarter of its value. This caused a sour ending to not a bad week, with the overall average a drop of 0.8% with 14 up and 13 down on the day.
Arcturus also capped off another losing week, falling 7%.
The top performer on the day was PDS which climbed just under 6% while Onco Sec climbed 5%.
No comments:
Post a Comment